List of works - Maria Elisa Mancuso

Common themes and challenges in hemophilia care: a multinational perspective

scientific article published on 03 August 2018

Comparison of thrombin generation for paired‐platelet‐rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor‐VIII inhibitor bypassing agents ⬇️

scientific article published on April 1, 2012

Cost&ndash;utility analysis of prophylaxis versus treatment on demand in severe hemophilia A ⬇️

scientific article published on March 14, 2011

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-half-life FVIII to BAY 94-9207 Prophylaxis

scientific article published on 09 December 2020

Emicizumab for hemophilia A without inhibitors

scientific article published on 04 June 2019

High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study

scientific article published on 26 December 2019

How we choose factor VIII to treat hemophilia ⬇️

scientific article published on March 12, 2012

ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study

scientific article published on 22 June 2020

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

scientific article published on 12 July 2017

Investigational drugs for coagulation disorders ⬇️

scientific article published on May 14, 2013

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

scientific article published on 28 March 2017

Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms

scientific article published on 18 March 2020

Platelets: much more than bricks in a breached wall.

scientific article

Prospective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication

scientific article published in 2022

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors ⬇️

scientific article published on February 15, 2011

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A ⬇️

scientific article published on May 1, 2012

Switching patients in the age of long-acting recombinant products?

scientific article published on 01 January 2019

Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027

scientific article published on 23 June 2020

Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients